CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

elexacaftor/tezacaftor/ivacaftor and ivacaftor

Last Updated: December 17, 2020
Result type: Reports
Project Number: SR0673-000
Product Line: Reimbursement Review

Generic Name: elexacaftor/tezacaftor/ivacaftor and ivacaftor

Brand Name: TBC

Manufacturer: Vertex Pharmaceuticals (Canada) Incorporated

Therapeutic Area: Cystic fibrosis, F508del CFTR mutation

Indications: Triple Combination Therapy (elexacaftor/tezacaftor/ivacaftor and ivacaftor) tablets for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Manufacturer Requested Reimbursement Criteria1: Tr​iple Combination Therapy (elexacaftor/tezacaftor/ivacaftor and ivacaftor) tablets for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: December 17, 2020

Call for patient/clinician input closed: February 12, 2021

Anticipated Date: January 22, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback